Internal restructuring
European Union
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.1 - Manufacture of basic pharmaceutical products

600 jobs
Number of planned job losses
Job loss
Announcement Date
14 June 2012
Employment effect (start)
Foreseen end date


On 14 June 2012 Danish pharmaceutical company Lundbeck announced plans to restructure its European operations in order to build a more flexible organisation and cut costs.

This decision is expected to result in 600 jobs being lost in the company's subsidiaries, mainly in Europe. According to the company representatives, the restructuring will not affect research and development units but will have impact on the company's sales divisions. 

Lundbeck, which specialises in medications for brain disorders, operates in 57 countries, including production facilities in Italy, France and Denmark, and research centres in Denmark, China and the United States.

The timeline for the restructuring is to be announced. 


  • 14 June 2012: Børsen


Eurofound (2012), Lundbeck, Internal restructuring in European Union, factsheet number 73896, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/73896.